P/E ratio for Alembic Pharmaceuticals (APLLTD.NS)
P/E ratio as of April 2024 (TTM): 34.0
According to Alembic Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 34.0498. At the end of 2022 the company had a P/E ratio of 53.3.
P/E ratio history for Alembic Pharmaceuticals from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 53.3 | 143% |
| 2021 | 22.0 | 27.47% |
| 2020 | 17.2 | 16.41% |
| 2019 | 14.8 | -27.48% |
| 2018 | 20.4 | -16.06% |
| 2017 | 24.3 | -13.15% |
| 2016 | 28.0 | 48.77% |
| 2015 | 18.8 | -38.61% |
| 2014 | 30.6 | 67.77% |
| 2013 | 18.3 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.